Predicting efficacy of neoadjuvant chemotherapy for advanced gastric cancer

New genetic tests set to advance orthopedic care
28 September 2022
A new method for inducing mesenchymal stem cells from iPS cells without using animal-derived components
28 September 2022

Predicting efficacy of neoadjuvant chemotherapy for advanced gastric cancer

Gastric cancer is a common malignant tumor that originates from the gastric mucosal epithelium. Being insidious and non-specific, the early-stage symptoms of the cancer are similar to that of chronic diseases such as gastritis and gastric ulcer, and are therefore ignored easily. As a result, 80 to 90% of gastric cancer patients have been in the advanced stage when they are first diagnosed. Surgery, with poor prognosis and a 5-year survival rate of only 30%, is still the main treatment for advanced gastric cancer (AGC) at present.

Comments are closed.